A share price of Kymera Therapeutics Inc [KYMR] is currently trading at $48.76, up 0.81%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KYMR shares have lost -0.53% over the last week, with a monthly amount drifted -6.95%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Wolfe Research upgraded its rating to Outperform on August 26, 2024, and kept the price target unchanged to $65. On April 22, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $53 on the stock. Wolfe Research started tracking the stock assigning a Peer Perform rating. JP Morgan upgraded its rating to a Overweight. BofA Securities downgraded its rating to Neutral for this stock on January 03, 2024, and downed its price target to $30. In a note dated December 19, 2023, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $26.
Kymera Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $9.60 and $53.27. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $48.76 at the most recent close of the market. An investor can expect a potential return of 5.62% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Trailing Twelve Months sales for Kymera Therapeutics Inc [NASDAQ:KYMR] were 88.55M which represents 55.33% growth. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -2.04%, Pretax Profit Margin comes in at -1.78%, and Net Profit Margin reading is -1.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.29 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.73 points at the first support level, and at 46.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 49.56, and for the 2nd resistance point, it is at 50.36.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kymera Therapeutics Inc [NASDAQ:KYMR] is 8.45. Further, the Quick Ratio stands at 8.45, while the Cash Ratio is 1.09. Considering the valuation of this stock, the price to sales ratio is 35.11, the price to book ratio is 4.38.
Transactions by insiders
Recent insider trading involved Esposito Pamela, Director, that happened on Sep 17 ’24 when 13500.0 shares were sold. Director, PAMELA ESPOSITO completed a deal on Sep 17 ’24 to buy 13500.0 shares. Meanwhile, Director Albers Jeffrey W. sold 5000.0 shares on Aug 26 ’24.
